Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma

Journal of Hematology & Oncology

Zhao Liu¹  Junmin Li¹  Xiaoyang Li¹  Zizhen Xu²  Wenfang Wang³  Kai Qing³  Zhen Jin³  Wanbin Fu³ 

[1] Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital affiliated to School of Medicine, Shanghai Jiao Tong University;Department of Laboratory Medicine, Ruijin Hospital affiliated to School of Medicine, Shanghai Jiao Tong University;Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, Ruijin Hospital affiliated to School of Medicine, Shanghai Jiao Tong University;

关键词: Diffuse large B cell lymphoma;    Oridonin;    NVP-BEZ235;    Apoptosis;    PI3K/mTOR;    NF-kB;   

DOI  :  10.1186/s13045-016-0303-0

来源: DOAJ

【 摘 要 】

Abstract We demonstrate the synergistic antitumor effect of oridonin and the PI3K/mTOR inhibitor NVP-BEZ235 on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma (non-GCB DLBCL) both in vitro and in vivo. The underlying mechanism may be multifunctional, involving apoptosis, AKT/mTOR and NF-kB inactivation, and ROS-mediated DNA damage response. Our findings pave the way for a new potential treatment option for non-GCB DLBCL with the combination of oridonin and NVP-BEZ235.

【 授权许可】

Unknown